These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 30009188)

  • 41. Current issues in delivering DCs for immunotherapy.
    Barratt-Boyes SM; Figdor CG
    Cytotherapy; 2004; 6(2):105-10. PubMed ID: 15203986
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Phenotypic profile of dendritic and T cells in the lymph node of Balb/C mice with breast cancer submitted to dendritic cells immunotherapy.
    da Cunha A; Antoniazi Michelin M; Cândido Murta EF
    Immunol Lett; 2016 Sep; 177():25-37. PubMed ID: 27423825
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Towards a standardized protocol for the generation of monocyte-derived dendritic cell vaccines.
    Erdmann M; Schuler-Thurner B
    Methods Mol Biol; 2010; 595():149-63. PubMed ID: 19941110
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Dendritic cell engineering for tumor immunotherapy: from biology to clinical translation.
    Bhargava A; Mishra D; Banerjee S; Mishra PK
    Immunotherapy; 2012 Jul; 4(7):703-18. PubMed ID: 22853757
    [TBL] [Abstract][Full Text] [Related]  

  • 45. IL-10 expression defines an immunosuppressive dendritic cell population induced by antitumor therapeutic vaccination.
    Llopiz D; Ruiz M; Infante S; Villanueva L; Silva L; Hervas-Stubbs S; Alignani D; Guruceaga E; Lasarte JJ; Sarobe P
    Oncotarget; 2017 Jan; 8(2):2659-2671. PubMed ID: 27926522
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Role of regulatory T-cells in immunization strategies involving a recombinant alphavirus vector system.
    Walczak M; Regts J; van Oosterhout AJ; Boon L; Wilschut J; Nijman HW; Daemen T
    Antivir Ther; 2011; 16(2):207-18. PubMed ID: 21447870
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dendritic cells in cancer immunotherapy.
    Le Gall CM; Weiden J; Eggermont LJ; Figdor CG
    Nat Mater; 2018 Jun; 17(6):474-475. PubMed ID: 29795222
    [No Abstract]   [Full Text] [Related]  

  • 48. Personalized cancer vaccines.
    Jain KK
    Expert Opin Biol Ther; 2010 Dec; 10(12):1637-47. PubMed ID: 20979567
    [TBL] [Abstract][Full Text] [Related]  

  • 49. MUC1 immunotherapy.
    Beatson RE; Taylor-Papadimitriou J; Burchell JM
    Immunotherapy; 2010 May; 2(3):305-27. PubMed ID: 20635898
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dendritic cells and cancer immunotherapy.
    Radford KJ; Tullett KM; Lahoud MH
    Curr Opin Immunol; 2014 Apr; 27():26-32. PubMed ID: 24513968
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Breaking immunotolerance of tumors: a new perspective for dendritic cell therapy.
    Rolinski J; Hus I
    J Immunotoxicol; 2014 Oct; 11(4):311-8. PubMed ID: 24495309
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Vaccines and melanoma.
    Ott PA; Fritsch EF; Wu CJ; Dranoff G
    Hematol Oncol Clin North Am; 2014 Jun; 28(3):559-69. PubMed ID: 24880947
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Augmented induction of CD8+ cytotoxic T-cell response and antitumor effect by DCs pulsed with virus-like particles packaging with CpG.
    Song S; Wang Y; Zhang Y; Wang F; He Y; Ren D; Guo Y; Sun S
    Cancer Lett; 2007 Oct; 256(1):90-100. PubMed ID: 17656012
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Immunization with heat shock protein 105-pulsed dendritic cells leads to tumor rejection in mice.
    Yokomine K; Nakatsura T; Minohara M; Kira J; Kubo T; Sasaki Y; Nishimura Y
    Biochem Biophys Res Commun; 2006 Apr; 343(1):269-78. PubMed ID: 16540092
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cancer immunotherapy: novel strategies and clinical experiences.
    Schmitz M; Bornhäuser M; Ockert D; Rieber EP
    Trends Immunol; 2002 Sep; 23(9):428-9. PubMed ID: 12200057
    [No Abstract]   [Full Text] [Related]  

  • 56. Dendritic Cell-Based Cancer Vaccines.
    Santos PM; Butterfield LH
    J Immunol; 2018 Jan; 200(2):443-449. PubMed ID: 29311386
    [TBL] [Abstract][Full Text] [Related]  

  • 57. How much help does a vaccine-induced T-cell response need?
    Weber JS; Mulé JJ
    J Clin Invest; 2001 Mar; 107(5):553-4. PubMed ID: 11238555
    [No Abstract]   [Full Text] [Related]  

  • 58. Recent progress in GM-CSF-based cancer immunotherapy.
    Yan WL; Shen KY; Tien CY; Chen YA; Liu SJ
    Immunotherapy; 2017 Mar; 9(4):347-360. PubMed ID: 28303764
    [TBL] [Abstract][Full Text] [Related]  

  • 59. DNA vaccines for cancer too.
    Yu M; Finn OJ
    Cancer Immunol Immunother; 2006 Feb; 55(2):119-30. PubMed ID: 16032397
    [No Abstract]   [Full Text] [Related]  

  • 60. Optimal control in a model of dendritic cell transfection cancer immunotherapy.
    Castiglione F; Piccoli B
    Bull Math Biol; 2006 Feb; 68(2):255-74. PubMed ID: 16794930
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.